Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + bacille calmette-guérin
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (atezolizumab), Intravesical (bcg; Direct Bladder Instillation)
01
Overview
This is a **combination therapy** of atezolizumab, an intravenous monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and bacille Calmette-Guérin (BCG), an intravesical live attenuated vaccine strain of Mycobacterium bovis, used as immunotherapy for non-muscle invasive bladder cancer (NMIBC). **Atezolizumab** blocks the PD-L1/PD-1 pathway, enhancing T-cell mediated anti-tumor immunity, while **BCG** stimulates a local immune response in the bladder, helping to destroy cancer cells. The combination aims to provide synergistic antitumor effects for high-risk NMIBC, improving disease-free survival and reducing recurrence in patients who are BCG-naïve or BCG-unresponsive. Multiple phase Ib/II trials support safety and preliminary efficacy, with phase 3 research ongoing[1][3][4][6].
- Brand names
- OncoTiceBCG Medac
- Other names
- atezolizumab + BCGatezolizumab + bacillus Calmette-Guérin
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on atezolizumab + bacille calmette-guérin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + bacille calmette-guérin.